WARRINGTON, Pa., Jan. 5, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announces the publication of results from its Phase 2 clinical trial of Surfaxin(r) for the prevention and treatment of Bronchopulmonary Dysplasia (BPD) in Pediatrics, a premier medical journal for pediatric critical-care healthcare practitioners. BPD is a chronic, debilitating lung disease typically affecting premature infants who received treatment for Respiratory Distress Syndrome (RDS). The results from the study indicated that administration of additional doses of Surfaxin following standard SRT treatment for acute RDS may represent a novel therapeutic option for infants at risk for developing BPD. Presently, there are no approved pharmaceutical therapies for BPD.
